OBJECTIVE: To assess the influence of enteral glutamine on the incidence of severe sepsis and death in critically ill patients. DESIGN: This two-armed clinical trial was triple blind (patients, attending staff, research nurse). SETTING: The 10 bed general ICU at Royal Perth Hospital, Western Australia. PATIENTS: This trial evaluated 363 patients requiring mechanical ventilation (median APACHE II score=14); of these, 85 had trauma. INTERVENTION: The intervention solution contained 20 g/l glutamine and the control solution was isojoulic and isonitrogenous. MEASUREMENTS AND RESULTS: The groups had similar characteristics at baseline, and they also received equivalent amounts of protein and energy. Patients in the glutamine group received a median of 19 g/glutamine per day and 91% (332 of 363) of the patients were fed via a nasogastric tube (median duration=10 days). The outcomes were similar in the two groups: (a) death within 6 months: glutamine group 15% (27 of 179) vs control group 16% (30 of 184); p=0.75; relative risk, 0.95 (95% confidence interval, 0.71-1.28); and (b) severe sepsis: glutamine group 21% (38 of 179) vs control group 23% (43 of 184); p=0.62; relative risk, 0.94 (95% confidence interval, 0.72-1.22). There was also no discernable difference in the secondary outcomes relating to infections, febrile period, antimicrobial therapy, and consumption of inotropes. CONCLUSION: This clinical trial did not support the use of enteral glutamine supplements in similar cohorts of critically ill patients.
RCT Entities:
OBJECTIVE: To assess the influence of enteral glutamine on the incidence of severe sepsis and death in critically illpatients. DESIGN: This two-armed clinical trial was triple blind (patients, attending staff, research nurse). SETTING: The 10 bed general ICU at Royal Perth Hospital, Western Australia. PATIENTS: This trial evaluated 363 patients requiring mechanical ventilation (median APACHE II score=14); of these, 85 had trauma. INTERVENTION: The intervention solution contained 20 g/l glutamine and the control solution was isojoulic and isonitrogenous. MEASUREMENTS AND RESULTS: The groups had similar characteristics at baseline, and they also received equivalent amounts of protein and energy. Patients in the glutamine group received a median of 19 g/glutamine per day and 91% (332 of 363) of the patients were fed via a nasogastric tube (median duration=10 days). The outcomes were similar in the two groups: (a) death within 6 months: glutamine group 15% (27 of 179) vs control group 16% (30 of 184); p=0.75; relative risk, 0.95 (95% confidence interval, 0.71-1.28); and (b) severe sepsis: glutamine group 21% (38 of 179) vs control group 23% (43 of 184); p=0.62; relative risk, 0.94 (95% confidence interval, 0.72-1.22). There was also no discernable difference in the secondary outcomes relating to infections, febrile period, antimicrobial therapy, and consumption of inotropes. CONCLUSION: This clinical trial did not support the use of enteral glutamine supplements in similar cohorts of critically illpatients.
Authors: G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg Journal: Am J Respir Crit Care Med Date: 1994-03 Impact factor: 21.405
Authors: Edward Abraham; Peter Andrews; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Michael Pinsky; Peter Radermacher; Marco Ranieri; Christian Richard; Robert Tasker; Benoit Vallet Journal: Intensive Care Med Date: 2004-06-15 Impact factor: 17.440
Authors: Noe A Rodriguez; Marc G Jeschke; Felicia N Williams; Lars-Peter Kamolz; David N Herndon Journal: JPEN J Parenter Enteral Nutr Date: 2011-10-05 Impact factor: 4.016
Authors: Jon Pérez-Bárcena; Pedro Marsé; Arturo Zabalegui-Pérez; Esther Corral; Rubén Herrán-Monge; María Gero-Escapa; Mercedes Cervera; Juan Antonio Llompart-Pou; Ignacio Ayestarán; Joan Maria Raurich; Antonio Oliver; Antonio Buño; Abelardo García de Lorenzo; Guiem Frontera Journal: Intensive Care Med Date: 2014-02-21 Impact factor: 17.440
Authors: Ruqaiya M Al Balushi; Jennifer D Paratz; Jeremy Cohen; Merrilyn Banks; Joel Dulhunty; Jason A Roberts; Jeffrey Lipman Journal: BMJ Open Date: 2011-11-14 Impact factor: 2.692